Overview
Pharmena is a biotechnology company that develops and commercializes innovative products based on the patented natural active substance 1-MNA. The company focuses on clinical research for an innovative anti-inflammatory and anti-fibrotic drug, as well as the market introduction of medical devices and dietary supplements aimed at meeting specific nutritional needs.
Financials
Revenue history
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 3.05
- High
- PLN 3.06
- Low
- PLN 2.99
- Volume
- 3.18K
- Avg. vol.
- 1.01K
- Market cap
- PLN 34.08M
- P/E ratio
- —
- EPS
- -PLN 0.27
- Shares outstanding
- 11.14M
- 52-week
- PLN 2.99 – 3.11
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLPHRMN00011
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 65.37k | USD -283.63k | USD -269.04k |
| Q1 2026 | USD 113.72k | USD -149.11k | USD -129.93k |
| Q4 2025 | USD 98.19k | USD -236.82k | USD -223.51k |
| Q3 2025 | USD 102.21k | USD -197.64k | USD -173.28k |
Results for Q3 2026:Nov 27, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2002-12-30. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Sep 11, 2012 | Commercial Companies Code notice | |
| Aug 29, 2012 | Commercial Companies Code notice | |
| May 31, 2010 | Shareholders' meeting convened | |
| May 10, 2010 | Shareholders' meeting convened |
Public aid
6 public aid cases recorded, with a total value of $296,872.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 16, 2021 | Other crisis aid | $76,971$76,971 | Polski Fundusz Rozwoju S.A. | |
| Feb 9, 2021 | Other crisis aid | $190.1K$190,059 | Polski Fundusz Rozwoju S.A. | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $10,398$10,398 | Prezes Zakładu Ubezpieczeń Społecznych |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
Joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations and sign on behalf of the company.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Pharmena.
Capital group
| Name | Ownership |
|---|---|
| 61.43% | |
Menavitin GmbH w likwidacji  | 13% |
| 73% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biomental Farmasp. z o.o. | $501.13 | biomental-farma.com | ||
| Pharmitissp. z o.o. | $301.36 | pharmitis.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-09-05 | Address change (Wólczańska 178, 90-530, Łódź → Ul. Gdańska 47/49, 90-729, Łódź) | |
| 2021-03-08 | Share capital change (1,098,475.80 PLN → 1,113,775.80 PLN) | |
| 2019-06-12 | Share capital change (879,505.20 PLN → 1,098,475.80 PLN) | |
| 2015-07-24 | PKD change (Removed: 10.89.Z, 20, 46.38.Z, 46.75.Z, 46.76.Z, 47.99.Z, 52.10.B, 86.22.Z, 86.90.D, 86.90.E) | |
| 2013-07-25 | Share capital change (703,604.20 PLN → 879,505.20 PLN) |
FAQ
Last updated: 2026-07-04